Pott, Henrique
J. LeBlanc, Jason
S. ElSherif, May
Hatchette, Todd F.
McNeil, Shelly A.
Andrew, Melissa K.
,
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (Finance Code 001)
Article History
Received: 6 September 2023
Accepted: 18 January 2024
First Online: 30 January 2024
Declarations
:
: All participants provided informed consent for data, sample collection, and medical record screening per the local Research Ethics Boards’ requirements. The Research Ethics Boards approved the protocol of participating institutions (ClinicalTrials.gov Identifier: NCT01517191).
: Not applicable.
: HP reports grant funding from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. TFH reports grants from Pfizer and GSK, outside the submitted work. SAM reports grants and payments from Pfizer, GSK, Merck, Novartis and Sanofi, outside the submitted work. MK Andrew reports grant funding from the GSK group of companies, Pfizer and Sanofi Pasteur and honoraria for past ad-hoc advisory activities from Pfizer, Sanofi and Seqirus, all unrelated to the present manuscript. JL and ME report no conflicts of interest.